alpha-aminopyridine has been researched along with Adenocarcinoma of Lung in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 10 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Daga, H; Ebi, N; Fukuhara, T; Furuya, N; Goto, K; Hayashi, K; Hayashida, T; Ikeda, T; Ishii, G; Izumi, H; Kato, T; Kirita, K; Kobayashi, SS; Kodani, M; Kumagai, S; Kuyama, S; Liu, J; Matsumoto, S; Mori, S; Nakachi, I; Nakai, T; Nakamura, A; Niho, S; Nishino, K; Nosaki, K; Ohtsu, A; Okamoto, I; Sakai, T; Sakakibara-Konishi, J; Shibata, Y; Sugiyama, E; Taima, K; Tanaka, K; Udagawa, H; Watanabe, K; Yamasaki, A; Yoh, K; Zenke, Y | 1 |
| Guo, M; He, Z; Jin, C; Li, C; Liu, S; Qiu, J; Wang, Y; Wu, D | 1 |
| Barlesi, F; Besse, B; Demedts, I; Frimodt-Moller, B; Fuentes Pradera, J; Gazzah, A; Kim, JS; Robinet, G; Soldatenkova, V; Vansteenkiste, J | 1 |
| Arriola, E; Monzonís, X | 1 |
| Jiang, W; Lizaso, A; Mao, X; Mi, J; Song, L; Yang, N; Zeng, L; Zhang, Y; Zhou, Y | 1 |
| Pan, D; Yan, J; Zhou, X | 1 |
| Li, X; Wang, L; Yu, J | 1 |
| Bridges, A; Gleue, CA; Shah, K; Wentworth, A | 1 |
| Liu, L; Lizaso, A; Xu, Q; Zhang, Y | 1 |
| Huang, D; Li, T; Lizaso, A; Meng, Z; Wang, P | 1 |
| Chen, P; Chen, Z; Li, J; Qian, J; Wang, C; Yue, D; Zhang, B; Zhang, H; Zhang, L | 1 |
| Hara, M; Iwakami, SI; Matsuda, H; Takahashi, K | 1 |
| Hochmair, MJ; Prosch, H; Schwab, S | 1 |
| Baglivo, S; Chiari, R; De Giglio, A; Ludovini, V; Metro, G; Ricciuti, B; Siggillino, A | 1 |
| Betton, M; Brosseau, S; Chemouny, JM; Goujon, JM; Gounant, V; Hanouna, G; Sannier, A; Zalcman, G | 1 |
| Bradley, KM; Campo, L; Fenwick, JD; Gleeson, FV; Green, M; Higgins, GS; Horne, A; Macpherson, RE; Maughan, TS; McCole, MG; McGowan, DR; McKenna, WG; Mohammed, S; Muschel, RJ; Ng, SM; Panakis, N; Prevo, R; Skwarski, M; Strauss, VY; Stuart, R; Tacconi, EMC; Vallis, KA | 1 |
| Hochmair, M; Prosch, H; Weinlinger, C | 1 |
| Kim, JE; Kim, W; Min, YH | 1 |
2 trial(s) available for alpha-aminopyridine and Adenocarcinoma of Lung
| Article | Year |
|---|---|
A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Aminopyridines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Tissue Distribution; Treatment Outcome | 2019 |
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
Topics: Adenocarcinoma of Lung; Aged; Aminopyridines; Anorexia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Fatigue; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Misonidazole; Morpholines; Nausea; Phosphoinositide-3 Kinase Inhibitors; Positron Emission Tomography Computed Tomography; Radiation-Sensitizing Agents; Radiotherapy; Tumor Hypoxia | 2019 |
16 other study(ies) available for alpha-aminopyridine and Adenocarcinoma of Lung
| Article | Year |
|---|---|
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
Topics: Adenocarcinoma of Lung; Aminopyridines; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 15; Humans; Lactams; Lung Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Oncogene Proteins, Fusion; Pyrazoles; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2021 |
Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report.
Topics: Adenocarcinoma of Lung; Adult; Aminopyridines; Anaplastic Lymphoma Kinase; BRCA2 Protein; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases; Tracheal Stenosis | 2022 |
Early Onset Pulmonary Toxicity With Lorlatinib in a Patient With Previous Pulmonary Toxicity From Brigatinib.
Topics: Adenocarcinoma of Lung; Aminopyridines; Anaplastic Lymphoma Kinase; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Middle Aged; Organophosphorus Compounds; Pneumonia; Prognosis; Pyrazoles; Pyrimidines | 2019 |
A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
Topics: Adenocarcinoma of Lung; Albumins; Aminopyridines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Paclitaxel; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2020 |
A case of one lung adenocarcinoma patient harboring a novel FAM179A-ALK (F1, A19) rearrangement responding to lorlatinib treatment.
Topics: Adenocarcinoma of Lung; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles | 2020 |
ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis.
Topics: Adenocarcinoma of Lung; Albumins; Aminopyridines; Antibodies, Monoclonal, Humanized; Humans; Immune Checkpoint Inhibitors; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation, Missense; Paclitaxel; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2020 |
Cutaneous sarcoid-like drug reaction caused by an anaplastic lymphoma kinase inhibitor.
Topics: Adenocarcinoma of Lung; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Biopsy; Carbazoles; Cell Cycle Proteins; Drug-Related Side Effects and Adverse Reactions; Female; Granuloma; Humans; Lactams; Microtubule-Associated Proteins; Neoplasm Staging; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Sarcoidosis; Serine Endopeptidases; Skin; Withholding Treatment | 2021 |
A reply to "ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis".
Topics: Adenocarcinoma of Lung; Albumins; Aminopyridines; Antibodies, Monoclonal, Humanized; Humans; Immune Checkpoint Inhibitors; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation, Missense; Paclitaxel; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2020 |
The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report.
Topics: Adenocarcinoma of Lung; Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Humans; Lactams; Lung Neoplasms; Male; Mutation; Pyrazoles | 2021 |
Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with
Topics: Adenocarcinoma of Lung; Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Immune Checkpoint Inhibitors; Lactams; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Nivolumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyrimidines; Sulfones; Time Factors; Treatment Outcome; Tumor Microenvironment | 2021 |
EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib.
Topics: Adenocarcinoma of Lung; Aged; Aminopyridines; Carbazoles; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Muscle, Skeletal; Oncogene Proteins, Fusion; Piperidines; Protein Kinase Inhibitors; Pyrazoles | 2021 |
Complete remission of intrathecal metastases with lorlatinib therapy in a heavily pretreated ALK-positive lung cancer patient.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aminopyridines; Anaplastic Lymphoma Kinase; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases; Spinal Cord Neoplasms | 2017 |
Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation.
Topics: Adenocarcinoma of Lung; Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Point Mutation; Pyrazoles | 2018 |
Minimal Change Disease Induced by Lorlatinib.
Topics: Adenocarcinoma of Lung; Aminopyridines; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Middle Aged; Nephrosis, Lipoid; Pyrazoles | 2018 |
Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient.
Topics: Adenocarcinoma of Lung; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Middle Aged; Organophosphorus Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Spinal Cord Neoplasms | 2019 |
The Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Aminopyridines; Aurora Kinase A; Cell Cycle; Cell Proliferation; Enzyme Inhibitors; Humans; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Mitosis | 2016 |